# Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC

> **NCT00709761** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 60 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** Lapatinib/nab-Paclitaxel

## Key facts

- **NCT ID:** NCT00709761
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-02
- **Primary completion:** 2011-01-05
- **Final completion:** 2018-01-03
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00709761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00709761, "Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00709761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*